Colorectal Cancer in Young Adults Shows Distinct Cellular and Genetic Profiles

A groundbreaking study published in Nature Medicine reveals that colorectal cancer in patients under 50 differs significantly in cellular composition and gene activity compared to older patients. Researchers from Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and the Broad Institute of MIT and Harvard mapped gene activity across more than 850,000 cells from 189 tumors.

Cellular Differences and the "Dark RNA"

Analyzing tumor samples from patients aged 29 to over 90, researchers discovered that in the most common subtype of colorectal cancer, known as MSS, tumors in younger patients contain a higher proportion of stromal cells relative to cancer cells. These connective and supporting tissue cells create a scaffold around the tumor, potentially impeding immune cells and treatments. Furthermore, the analysis identified 215 genes with higher expression in younger patients, many of which produce long non-coding RNAs, including approximately half belonging to the "dark RNA" category whose exact functions remain largely uncharacterized.

Clinical Insights and Screening Implications

According to the American Cancer Society, colorectal cancer diagnosis rates among Americans under 50 rose by 2.9% annually between 2013 and 2022, making it the leading cause of cancer death in this age group in the United States. Dr. Yaron Rodnitsky, head of the Colorectal Surgery and Proctology Unit at Meir Medical Center, noted that younger patients frequently present at advanced stages. While the US lowered routine screening age recommendations from 50 to 45, experts emphasize that persistent symptoms such as abdominal pain, rectal bleeding, or unexplained weight loss warrant immediate medical evaluation regardless of age.